A pilot study of topiramate dosages for migraine prophylaxis in an Asian population.
Topiramate is known to be efficacious in migraine prophylaxis, but its optimal dose has not been systematically studied in the Asian population. Here, we show that a fixed low dose of topiramate 25 mg/day is efficacious in migraine prophylaxis and also attest to advantages in terms of medication cost savings and more favourable side effect profile.
Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Outram Road, Singapore, Singapore. gnrlyl@sgh.com.sg
Y L
YL
Lo
S Y
SY
Lum
S
S
Fook-Chong
H C
HC
Siow
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D044466:Asian People; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000208:ethnology / Q000517:prevention & control*; D017063:Outcome Assessment, Health Care; D010292:Paresthesia / Q000139:chemically induced; D010865:Pilot Projects; D012846:Singapore; D000077236:Topiramate; D016896:Treatment Outcome; D055815:Young Adult
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose